Alivio Therapeutics

Name

Alivio Therapeutics

Website

https://aliviotherapeutics.com

Company type

Private

Founded year

2016

Operating status

Unknown

Headcount range

11–50 employees

Short description

Alivio Therapeutics is a Boston-based private biotechnology company founded in 2016 that develops therapeutics aimed at precisely tuning the immune system to treat inflammatory diseases, currently operating with 11-50 employees and minimal public disclosure.

Ownership category

akta.pro rank

Product category

Inflammatory Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Inflammatory disease therapeutics
• Immunomodulation therapies
• Biopharmaceutical drug development
• Immune system modulation
• Preclinical drug discovery

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Alivio Therapeutics develops immunomodulatory therapeutics for inflammatory diseases by precisely tuning the immune system. The Boston-based biopharmaceutical firm focuses on pioneering new approaches to treat inflammatory conditions through targeted immune system modulation. Founded in 2016, the company operates as an early-stage (preclinical) drug discovery entity.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• Nimbus Therapeutics: Boston/Cambridge-based immunology and inflammation-focused small-molecule and computational drug discovery biotech. Comparable to Alivio as a similarly-sized, hub-based inflammation platform pursuing differentiated mechanisms for inflammatory diseases.
• Inflazome: Inflammation-focused biotech developing NLRP3 inflammasome inhibitors (acquired by Roche). Comparable to Alivio as a small-cap inflammation platform whose targeted immune-modulation approach attracted a top-tier large-pharma acquirer.
• IFM Therapeutics: Innate immunity and inflammation biotech acquired by Bristol-Myers Squibb. Directly comparable to Alivio as a small inflammation/immune-modulation platform whose value was ultimately realized via a large-pharma acquisition.
• Jecure Therapeutics: Preclinical-stage inflammation and NASH-focused biotech (acquired by Genentech). Comparable to Alivio as an early-stage inflammation platform that demonstrated an M&A pathway for hub-based small biotechs in this space.
• Dice Therapeutics: Inflammation and immunology biotech developing oral small-molecule therapies (acquired by Eli Lilly). Comparable to Alivio as a small inflammation platform whose targeted immune-modulating pipeline attracted a large-pharma transaction.

Emerging players

• AnaptysBio: Clinical-stage inflammation and immuno-oncology biotech developing antibody-based therapeutics. Comparable to Alivio through shared inflammation focus and antibody/immune-modulation therapeutic modality, though at a more advanced stage.
• MoonLake Immunotherapeutics: Clinical-stage inflammation biotech focused on IL-17-driven diseases. Comparable to Alivio as a small inflammation-focused therapeutics company pursuing precisely targeted immune modulation in chronic inflammatory disease.
• Apogee Therapeutics: Clinical-stage inflammation and immunology biotech developing biologics for atopic and inflammatory diseases. Comparable to Alivio through overlapping inflammation therapeutic area and immune-modulating biologics modality.
• Siolta Therapeutics: Early-stage inflammation biotech developing microbiome-based therapies for chronic inflammatory diseases. Comparable to Alivio as a similarly-sized, discovery-stage platform pursuing novel immune-modulation approaches in inflammation.
• Inotrem: Clinical-stage biotech developing immunomodulation therapies for acute and chronic inflammatory conditions. Comparable to Alivio through the shared focus on tuning the innate immune response to treat inflammatory disease.

Market position

Customer concentration

• LinkedInlinkedin.com/company/alivio-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alivio Therapeutics